ࡱ> FM.Kb|JFIFddDucky!Adobed0M   #%'%#//33//@@@@@@@@@@@@@@@&&0##0+.'''.+550055@@?@@@@@@@@@@@@"!1" 2A0P@`Bp#!1AQaq "02@P`BRb ]<@ L L L L @ @ @@0C110C111101h)1 &4C4`X B P&mP5Djcd!a@&PH&*mP`P&`Li0L*V! Rm`@ R0#d)AՒ0@ eC(Ę&H!(&Į@`b*D b(kQ= @8hCa4Bv@d)l%04&1*BT)`*BJ@P$ 0 0C@m4($`0t֡7"$66M6L܉M΂]!*bW4KCB&m Ar%l̤!ЧD" &h&)Uȝ` \'rTԀW:v413UMԌMT L%h)rM&4CVhhM56Jj@C)$s)"DPB!bI5M%Ы;T 5'LJ!#BD , )dڵJ 3*Ն{gdM*cD[ t*P9lv(RCW7;D)Km\4!;B%N&SijQi Gu6-sIuPJѐKe"+455)qM\h7$Աԣl9lTERb)#L;Sj7\j@b^*d&H)sR"$4qBֳr+!M⦚t4b؆! i,őYɋ:NTCF2RK-ES&5Ahȶ!V!CWpk EA2YuKFEѝX)D<MSL0n*i)g"gCYZMUHf)5,WΤLVYUQ)H$ܦFѪLQ-t 2 IH ŠԄ!n:R̩X芫U()&i2hpCDZ!M9CHLcBZk*)8.H, CT;Lk-QkNtC"Dᗖ UJTR (*E@IE)T8n;D]2ɍr5͢"vRR:J(BШ:άj8)= t"I$&-F쑃N:{N$r*`K#MmidTy5-y [tT &^ L $hIHґr15rRPHLGSB D5cYBi (bmɝ͔ I+p!M(T H].I(cyҒԖ-R%jjR, R43f:TR ֔Lji̹Ji2t#+:bi:I/;h9rf:+sV$VtW;! j ℨbB*CYZ)LТ`ZI.t%g TU@LT8M^T8,ILE%W%EMAJySIh:$bo!zhpgA4rȡ*!ŚgHGM YY t*D h*RB\i*M!!%T(-<ǦTY()K$hJ!Mt)b!҂BY$RWU8)46p+TFD%X&ZB ZZMaQ(B(qIRr4!qPE6Efm4YTHZ$ڦuB03F`Ӆ*hڌ i RUC@FU&PEPjei KΒVfX4HDH$b*,&\cj"ª ""*P:F "QF1 HAjGQCΓR-E0mYN(s,kJUz,-HV ӚL\`E;j=3@, \ZrJnΔʧ Rh-Rgm IJ)(Ph!֒HES;@#d"(K\VZf`S0*5JjƯ;cj@A1jPA"ZH%TPMf-& R7H4gT(%-ҳpQK96#U t"4iٛmf)zeE^VLQ*mHyI[B42j%˜Wg>.\xsυ/2Ĺ~>g?sW?m~|*%isDRyy_sQ?GfyuG'^|TK_c?om~3'q#̦J'!:%N!rT \J*ua8,W(+L31YNN%qA>Z* Lsu"JOnd/Njl'2JTcp#*S\C )1'+l*\ RJ\9~)`$FWPH `ms?*V|*%FTuQT娟sSCTvbZK\LJ*אn|:SGu_=Zf7#fuz2St 4>3AeJJ^\RyԼzQgU`r]8(b<˱_}M Ϋ x\E`ΪXҷQB6@jZ@WS+2;Z@\_:aΫ2sͺ~,3P9~@%bKY\F*c-2RfRa'\93댧ZߗsF3p53#A'~0^ Ԣ<tY>%q3&8qST.V%f̙ͦƉՅF8nYJψ ֝M|\PK$KA̋A4 Wg/]8xtus®TLNVݼT:rVRμhƁBΦLS^SK ZWeKY|vtu9.gֺ u gý:sS9j%zG%2h:Os+:s̪;>+!h3ƙԈǯZ־q} 稢[-gfiYh9L eW|gj=N.ZW3|fgը|m$s54LeZYEX \{z.kh&u]L~ʣ\Lj+4&3g2phhih:c /^P{uXI8 sܷ.㾲Bkئys +ռN>spr0r Ij [i٪m. zĩH}면S48f1q^+=g]LB1?Fj&EWePďZ,xJ{К=f3η3,&r&lZӠ f!QygW]KC8rfi(Z3膝j?bkZ~ѓ+4)=s!ӧY3tc,Uֱֳ'f ޻KkkٜaeYgi sZI99ήvr:֜ۏV֬zs>EVU]3>PukZRS\^Gp tt[}Y2h3zդp̡3F yMTrN&CFIRR!fv\glE=k &Fu02J52g>C r #Lg ;^Ck0r3DW_9WNPT;0zG9dkݪQlbkZS׉*Ԇۭfjy\ǯK|䅩{K2ag/\KA)5si2+w ϯZY׻Y&l3u]f#2L3Z26GZӦL뙑dΖk-_۬c&}yusf:uc= Y`WJMoks4\..u[dkM @k[@/E{TӠZ[LʇRkNoA&7ˬuɕ9E!T}3:F :u~7٫\nz }73f&~!v&i5+C=o_XL4\8,Q;t=E2N-smҫy]iofܖ>p }ۂ&8p]/3J:׊+j}AQ˧3)ۼ`HLgZ+0ˤpjۂ\h"֗|| t3EIi=khVӟ̌vc>#ޥqtr|gZYs:6͹ Y]R/%:Rs;\nS} kڱLk&=iXsp%[Y3s_ 4崪qmQnWU0C'mS`%g GZd\ ѫu dz'gn]&4Oa3Td3bWD3zgejd<!?TuWKLZ;๜gJYx#6@Y'q7h͝}yˬƒi}?!ZUjYukgzLoZ@dkG\qY9Y֡zkt0&Bj~EM =L̜kjtz\g{>fd9fw; J&?LtdQm޸[gXL_jQ֋&NzMmRoE3zz.z#u,u 1NiMkc}rL=SLќ8Z8Yz^&Z&4taUtEsxijy jAL 82'X V{WPaPs5aheHz^X۝}=ymtiɽvqƺ&W[L:0¨ ɝ+32>i7sLk][U HR.bG-huYփGLjz[YiE]y=e'p?X,Wح$S6)w`\wXָ3kFsMk&~sbܜDUh2L]\榶ndXOY\OSg:IPLgmu{Y kZBYY7cז&f4[=z=ecttEΐOgM3 g($|UfhYD iLg&W5rkZרɐ57=z_^讳Q8ɜx[muvf[w32{3f:jvj^ W׎ hӲ*f >d5ՎΧ+*Zl pT70߱ ׳A7:Fpw NçHӭ:ukv ւvcJ2+zSH.DJ2t:20h1C]Mju\:z{k^ n PlPM}{K5Z\Q-[tGPwM\܋Hp~V}}OWK9 ` p:S1kZ3Ȼ -.oٝls?&yVg-ރLtAߵrU%C[ӤzΤbjcguLiEU^1nU ћV ?]S4*zItg}Wι\W9'5m0S@Jjh*h&yR'l.z{oO9oPRaP=Gc*ՙ,KE,-*S}5ut' ٸ"Egf;]b~jf9,2`!ɕ9 p]n bQ{tNՓY`֖tSZ3! 3t6tRbgV]$p2F_^lk3GaDN3fspͨVrCSԳ&X2ٜkMT׳]jdvNC^ͺskַI1r^ӌE֞]u%u.3;9̴2bm}]_c e֮dkӭ%?4<W 9 -ֵN4G49 EhT@!A9aUtr$҆yFj=`ZsTӘ23us82,CT\ ?Wn-r:=}M[mr1jV3M=ӧQthƙ ˒sz֬X%-]gU|odZ9˿c2-s5gfD\2kSy/KFRq[7öuvoפJ=~1Ss?Q7ˑPH )fɕEۧ9=sWfTifɱYɜQ9!o fg,άond~t̄!,Ĭ*FCy v|)ueIAm٧YxԳWĖt&!C&d@ofUϮ\\붷t}:cZzjSNRtI&WAհ9Lg0ݲNֵyװ,=giPu iΗ`Mf}uޝ`yp{]=(c7K%Z3`umJf193zkyxk|s91F; v9]1J&d]]ۨt+1׬4Fg7=}M_ѝӭQW)LQC [cgf Kk+3cY5ԃ{?5ۜ^Z3e8ζh'[/ ڂQ_RfulpXaR7Y>5~3Uu-bNˢtX煶hhgדZӦdY]6N;jg$:g?/56ڹ;';A+,zKg YZ24`&Fz9E.:ւkLtֻ8ˤPem1֟f9÷gWBR-^ڜ(ٜn̦f*N{@YYQ4n J4@3y0K:;\x3ev3]9|`퐷RYvO-&F;gkjv3/Zz(u3&G~VvkQOS&uPʺgla29ʱҹj gZgʠ F\f{d@Cvd&}zZeZ֟bޔE+ KI7vO#isl3H+35;֊jd=4{49LwåhS:Mp8*-AoSN*g<&>nA m^g3Qδ\d͙U9RM.5̔vtd 'S.6N@H te\vV3#fvjC-roq]Lu>~>sMN)ӓ$WZui1Lpμ-34k)Fknu֮uDX2^3g zW:ڦz2^ەnmhuRd d:nnp8q=σ9f@>ަyuYΪlL(-\.&_~us3}MCfuh-0g2+gx=9g!9=: oP3Pѓ׭1iZ18MN\l-e6sS󬼺7ty֪ Zjioј fwkJss8~֚sWY678}9Ү3zd4teSmƲ/Zæ7c|\g6fhX 3gétֵ j8>'ΉVo+֕1< .@Z2ёMYᅝ!I=hC_֑Uq[_Yzޓ}cKX]o&GJP S흐/SFQJEo9W띌 :GUε7ZB![55i)3v+P֕dє]mg]F:iMɌX0j13{{wnڿ_g ~׫ޔ+H붳IOg8Yg7ւ=m_:I'n7zw=@e+mOcdmsײgRe,4 *uSzN`ʍ̖zdM t&@ڀڳ\vQ4esΕ:[GP3_mVz##uikkFC+9oƴ˃ \vӯ^S.I%#3]reKW3Y׌5UP"AXGk[\d7uk(5{h*9Ajgmi]fhDk[PfB:QZS5iuf9sUh/AZbdq}/Յκ.sS) 0PuNdɭOYj|ƃNګ+3Wm=FiN@"ȩ.3%;d@M+3dəR v*g_ml5d /&]fz5dg[@&2vӕtk_>kzk kFQ\%芭Abz.E]/RgMN9)C:U3am2s[⺉,Wx.z:3z5gy 8&1Ψ5 tYwZtʏ&M!9Ӥ 粘5٥ Qu0ڌjuc9ˤ5پawf ^IdPJϪ2aDlk}ugBhV;It-P{fjM+ 2̔W*ՆJfsd4?̦ic] vjsu d}9Ur|%;/|z[ +Q֣˚OdOol&{ہKIˠ/ZwYE9 2UE_KYQg;G2ڳy>83 }WM!jLd@NibWEku?!.h7qLy}jJRȰSvX*C 9+Ygrj9Kc :ӧ[.ig%{=vW)bGtzM'Q|> `)sQSPY_fR3Pscۭ?&N{hȻј3P Ӑͯ V S{u uu]A;?6Nt0a`}g yY{-q:X4vm)u:XV&n.OBB:MwwΧ3u3χ>4GZt%S/KKs|̴W Ӡ?[Zt[w "b:VᴎOjEVH{.Py\jK b8sDF-M73WUHk9 4|`V|&AYDl.ߕZxekHx*ȷ3\8ounRƧ*\9vbs4itLD&P˖KOQV\x%Mme;{2sρ?gUy3;Em0Yrw?μ2~'i\[K.f7>`*Oy/*W x'5iep:Xp\, -JKeiqcaK.XBY/,-KX>gυ ϋU֝?GN =B:_ͱ]p<|Apj[.៝kWpj-˗ -Qbߋ ϛ|οo7[O_c?ޙrXoڤAr,˩dXrb_Fܹ|A,] ܾ{rf.eh-T *Q*T(J(~u+J /#ZX<~^VX/ })~}1}^JZƱ6/Q1}S^FY௢>'n " ~ִ/H%^Z 蝉xD/Q财/m%au^N(R,Y_(͞e*ǯ2 +l"$2B<'9֛H=Iz۶1 w.4 (󤔨y#Y[v1>Hf촲/lI1 HX,-<"YegYEU!6'b",Ouܲ[,b#(&%pR6z",̶@ƊIt( 7?*R<>Y"4Mg$x87vLi G''B,셄7#,z # ^FpGܻ!*<|U4Ydl>=W/mlD$Hu^M^œx+؄.HWr$?sXۤ]'81G y$|"OR[#Y"~G^Im.Gӧ?&l(^#28{U"헅Y)GUD< U{ݎ?RVY%r$Qt!.}vD%A#dm3OQy-/<b'%܍4܈Ȃ̞ p*'+ԽϔQ;rJn:q@^r4/ Djv|Uuݍ&u^rEOcFK'b'<7ek;w,r&hOɩd>%*%XK!C?/s.ǩ䗤uT1z.R!Po뫇dR> a TY de^k _rs$y=>]} ^i3/ m K)d^cܓ>7Y2F0ps w>*xX$Z%-F|Z ^IL?r-% -i,eID~B!<'O$`]R1,FB fbEScKG-^M-r?o='粖G W$uSu\lKV^엃0>3i}oZUU2z A1 Tߦ)&2F^zc&YHj)i$d|DK'`!T^G̓2yYUeuC>}U4ݶ?, f F L}(ne +KaW+!}Dnɑ$MdɊ!)DĒJV)8^ 1֓"^ p5 زVv"::^Ic܏>='Otz"Ϗ_r.ߑ!Agl=OG/YJc+{ pF`Dg9!T)݋b1b1l͍% ampz[ N4%lKT^gGe Qx~‡5OKW'|S,>p<<[dNt='',m-%^I$=Kg>=p"XđKj/_"Gė WW2Q/G4|zgI^ļ uge#?r/ݐ@I#@Ң&OGv8^zp|J1u%`5nW>K"X>8FEz-o[%DrK<kKVؘ^v= T=4mPr~N=kK(q/Vyx%]pO <ɛ Ƹ+rbH ~;ݐقVH{\K-bIc!`RBPK,)Y/,HDlnB? ?")~o2>%ɉkCK/F~ڸɚ/',|BSLoE剡)Z%'Bx)$=_:Dr%=7&kOb1,ull@B#KE zL6F{24Y=-$py&,ɛ9") b%d2J )^p&g>;#/-lD% D<]q6ϊB\  %9>S|GS3$DuvCgw9JK11DdU)G]d䅒ƕ!{K,|'=pR>H5/cI߱[mDvB"`A%m&4Hn/Qd ,]QBs|b,n^Ii-%H|V7eř|mTV/,Ci$4l] U/$K<4sI+'ɼ0%q"%KDU]/HHވƊ9L UM񶞂HuN+rJ\ !ܡ1:ppLKj[?!uرq+#u|3ؘ0DR[dnG0K%f)99&) 2z-pHp!-/,7%M>+ܡ9eFKtX-VɊ'n,F[%BX'%%A$Lz cyvOgleIHV^KbV ~Dc^4$xG!:&e('^9{8I I}nm[nN[""u:R"F$Kؽ*+,#mS.3m Ƶ^>)%g0Xt]UKeBҥ~670(1GirrK?:.X )!a7%id!*X8Dr# Qc O'XJVBPUlN|؄_bt!{Hd,E[ݑd|)pxe[!+/) $22nF!\KfD_Y(L$ X)DbIcs.2~Tgq)'d ƖNǁ=82':{2Q϶:>J%.7)ANz^ Kvxܯv"VĞXK>}<.Zxbo?bd=zX[igNK$u%ĐdutCt~Jȧ#HD!-du=DQKLݒǨ#_BK!HP[܅YPBx<OjE[$ 얆߰TğQ-=! 0su*D4EI JD|Xۢ6-A =Q=)x䥍ė)$!"u:rd_Tʢ[hIzHH\\rd+|Bnbl)nV CnngQ,e=^⶗-wnFUB'}" {"2VD`Ky>=.ܐJع& ҒJ>)D T u@#d'/HYnζGU%K#cX)y.>]{׹Diz6Og1 #FɃ2V x'aP (^g/bom[-0f{1dnpILOkdrJ'ɒdnN`L8=-K,GZ>*KoO-u>+ܕD䬓="p[!/ $H$}uE G&i:!8!)6KKqZP;VGd#t"4yGSO'>]+C?q%@o}t?g9!nI IgstZ$l``F?|>O'ѷɋ9zB]3BtIz#t9# %$߁,$َu'_y:rx.1[[BҶ'Β/B":u//؅ȥ4)r_n$AC{! ،dq=6{a'ۅ*.ZrBҶK<#<*qMu\iVF#q>n?#Jz^7#m% C>tKΒelY(n(d!aoLQ*,s 6Uΐ41N%!|V!c{L!g}>]^䯹nX4ް^ &䄨%J-؞E^HP䎾Yw,/$ox<I$x2^4pz <DF|z{9 ,//JP~GȏېrmAI7S-%)?' ,N,)$\Kܼ"{Vy'7>[IjY/ܡ<^OQB i .9܅x$"/|-lN BDrU-yjO$NF$b Me< [ik؎9"HE{g Q`>ļQ%))Ye[zL(d"<*-ؖGT>ݯU,Wө e~4luoqN^9.׭u4%s /bȖUٞ Vy/%i.x!nI' ,m۷]" z[^'$".o'& (Q}<:Fd6Y/; r?(ΰFM$9%pY.7*ˡ.KrlbXJϗlLFcs&Y Oٵ bHTOpB-EđY)zɒbtVγ2ynJhY-/Ư=(d%//bYCycOb!K)/-Eg,bY RzK$} n3SQ cmcbLd-+$,/Y(xҰf bXoIu%x%VBy'd4%;'8H1&J#a;Ę"`BJ,^^璈TK%kk^#G)pY &OmH$*2%躱xc\P9rz]Bd'\唰>ݷ'>NbuR7N|bK& RDI"{R Y"~p>k}{9gb^ \;~J#/:K#9XM𱤒1oqU2Y%Гs sGK6~%2Iv1//rd/("hXųԷIX-ޓ;QB!;O{!u蟗ૂ۳6ȋ3 b^u[w*cmHYgedVmqY?'C< iFli\*9b[&rP^߱J]DFD>K~!amO:yx,ܷdp9r.O{֘_'PlϏU<YjķODh3d =#s0+92{ ,g5'Ǫydƒܻ̕lL^C% /}rVH_qy,[,^,m,]zlm,v)rBB,dux(D/=Ks#J pLI.ddǡ,vEh=M#m<ˡs#_џbй&HW$!Y'/ Ix!k%R "OK!-!{K|^N|fX3$bEi ܫD$%c$$6%/Q!Ξ~ڷf4dZI>KYkB]A?KoRx(n/^^I&~ >CԂ +=~ޱ} ~Tk o/^OV_G/QsdU'J[*k~?_ Hkk*,WԗWgE?ӯ;je<ܩ77777777777777777777777777777777Ŝ6(   9ZFwww.fda.gov/cdrh/devadvice/313.htmlZFwww.fda.gov/cdrh/devadvice/314.htmlR>www.fda.gov/cdrh/devadvice/pma/hTwww.fda.gov/cdrh/devadvice/ide/index.shtmlXDwww.fda.gov/cdrh/devadvice/32.htmlXDwww.fda.gov/cdrh/devadvice/33.htmlZFwww.fda.gov/cdrh/devadvice/351.html\Hwww.fda.gov/cdrh/devadvice/3131.html\'Hwww.fda.gov/cdrh/guidance-about.html/ 0DArialngspīLpv 0( 0DTahomagspīLpv 0( 0" DWingdingspīLpv 0( 0 a .  @n?" dd@  @@`` |ttL      ,R$.Kb|M8 0AA@8wʚ;ʚ;g4mdmdv 0ppp@ <4dddd` 0L\ <4!d!d 0L80___PPT10 ? ,O  =--#Overview of FDA Device Regulations7Bob Assenzo Critical Path Institute bassenzo@c-path.org$ ,Overview of FDA Device Regulations - Outline--(fIntroduction Establishment Registration  21 CFR 807 Medical Device Listing  21 CFR 805 Premarket Notification 510(k)  21 CFR 807 Subpart E Premarket Approval (PMA)  21 CFR 814hOverview of FDA Device Regulations  Outline (cont.)(5-((|Investigational Device Exemption (IDE)  21 CFR 812 Quality System Regulation (QS)/Good Manufacturing Practices (GMP)  21 CFR 820 Labeling  21 CFR 801 Medical Device Reporting  21 CFR 803"Introduction to Device Regulations##(FDA s Center for Devices & Radiological Health (CDRH) is responsible for regulating firms that manufacture, repackage, relabel, and/or import medical devices sold in the US. Additionally, CDRH regulates radiation-emitting electronic products (medical & non-medical) such as lasers, x-ray systems, ultrasound equipment, microwave ovens & color TVs \\w2Introduction to Device Regulations Classifications33(Medical devices are classified into Class I, II, and III. Regulatory control increases from Class I to III. The device classification defines the regulatory requirements for a general device type.  :Introduction to Device Regulations Classifications (cont.);3( Most Class I devices are exempt from Premarket Notification 510(k) Most Class II devices require Premarket Notification 510(k) Most Class III devices require Premarket Approval For classification determination see: www.fda.gov/cdrh/devadvice/313.html "Z&Z!0Device Classification PanelsMost medical devices can be found in 21 CFR 862  893 FDA has classified and described over 1,700 distinct types and organized them into 16 medical specialty panels, e.g. 870 is cardiovascular; 886 is ophthalmic The CFR gives a general description, use, class, and info about marketing requirements www.fda.gov/cdrh/devadvice/3131.html QZQ"+$!0+O 5Introduction to Device Regulations Basic Requirements66( Establishment registration Medical Device Listing Premarket Notification 510(k), unless exempt, or Premarket Approval (PMA) Investigational Device Exemption (IDE) for clinical studies Quality System (QS) regulation Labeling requirements Medical Device Reporting (MDR) Z  ZEstablishment Registration  21 CFR Part 807..(Manufacturers, domestic & foreign, and initial distributors (importers) of medical devices must register their establishments with the FDA. All establishment registrations must be submitted electronically, unless FDA grants a waiver All registration information must be verified annually (Oct 1-Dec 31) Foreign manufacturers also must designate a US agent Most establishments are required to pay an establishment registration feeZ RMedical Device Listing  21 CFR Part 807**(Manufacturers must list their devices with the FDA. Establishments required to list: Manufacturers Contract manufacturers that commercially distribute the device Repackagers and relabelers Specification developers Reprocessors single-use devices Remanufacturer Manufacturers of accessories and components sold directly to the end user US manufacturers of  export only devices |P|>     rPremarket Notification 510(k)  21 CFR Part 807 Subpart E::(If device requires the submission of a Premarket Notification 510(k), it cannot be commercially distributed until an authorizing letter of substantial equivalence from FDA is received A 510(k) must demonstrate that the device is substantially equivalent to one legally in commercial distribution in the US: (1) before May 28, 1976, or (2) to a device that has been determined by FDA to be substantially equivalent www.fda.gov/cdrh/devadvice/314.html P!0 Premarket Notification 510(k)  21 CFR Part 807 Subpart E (cont)A:( 5The Medical Device User Fee and Modernization Act of 2002 authorizes FDA to charge a fee for medical device Premarket Notification 510(k) reviews. Most Class I and some Class II devices are exempt from the Premarket Notification 510(k) submission. See www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/315.cfm69 Premarket Notification 510(k)  21 CFR Part 807 Subpart E (cont)(A:( (CReview by Accredited Persons: FDA has accredited 12 organizations to conduct a primary review of 670 types of devices. FDA must issue a final determination within 30 days after receiving a recommendation from an Accredited Person Accredited Person is exempt from any FDA fee; the third party may charge a fee for its reviewDD TPremarket Approval (PMA)  21 CFR Part 814++(Products requiring PMAs are Class III devices that are high risk devices that pose a significant risk of illness or injury, or devices found not substantially equivalent to Class I & II predicate through the 510(k) process (Fee required) The PMA process is more involved and includes the submission of clinical data to support claims made for the device See www.fda.gov/cdrh/devadvice/pma/ *O!0f pInvestigational Device Exemption (IDE)  21 CFR Part 81299(An IDE allows the investigational device to be used in a clinical study to collect safety & effectiveness data required to support a PMA application or a Premarket Notification 510(k) submission to FDA. Clinical studies of devices with significant risk must be approved by FDA and an IRB before study can begin Studies of devices of nonsignificant risk must be approved by the IRB before study can begin See www.fda.gov/cdrh/devadvice/ide/index.shtml  P0*M=*!0Quality System Regulation (QS)/Good Manufacturing Practices (GMP)  21 CFR Part 820TT sThe quality system regulation includes requirements related to the methods used in and the facilities and controls used for: designing, purchasing, manufacturing, packaging, labeling, storing, installing and servicing of medical devices Manufacturing facilities undergo FDA inspections to assure compliance with the QS requirements See www.fda.gov/cdrh/devadvice/32.html tt!0Pr4Labeling  21 CFR Part 801Labeling includes labels on the device as well as descriptive and informational literature that accompanies the device www.fda.gov/cdrh/devadvice/33.html "w"!0wTMedical Device Reporting  21 CFR Part 803Incidents in which a device may have caused or contributed to a death or serious injury must be reported to the FDA Certain malfunctions also must be reported The MDR regulation is a mechanism for identifying and monitoring significant Aes www.fda.gov/cdrh/devadvice/351.html Z%,#!0Guidance DocumentsGood Guidance Practice (GGP) relate to: The processing, content, and evaluation of regulatory submissions The design, production, manufacturing, and testing of regulated products The inspection and enforcement procedures www.fda.gov/cdrh/guidance-about.html &Z&"$'!0  ` fy`ff3` Mj*333FV*` ffNNt^X` ffNL|>rL` +T3f3f` MMMff3f` Lx[he2` {$$>?" dd@,?nAd@    @ `  n?" dd@   @@``PR    @ ` ` p>> $(    6 " `P  T Click to edit Master title style! !$  0| " `  RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S  6X #" `^ `  Z*  6 #" `^   \*  6 #" `^ `  \*z  NA޽h ?texture_mid#" @@ +T3f3f80___PPT10. ` Textured  0(    <(ǜ #" `   T Click to edit Master title style! !  0ɜ " `    W#Click to edit Master subtitle style$ $  68Μ #" `^ `  Z*  6ќ #" `^   \*  6<՜ #" `^ `  \*z  NA޽h ?texture_mid#" @@ +T3f3f80___PPT10. `0 zr@\ (  \ \ 0 P    P*   \ 0Lƣ     R*  d \ c $ ?   \ 0ɣ  0  RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S \ 6ͣ _P   P*   \ 6pѣ _   R*  H \ 0޽h ? 3380___PPT10.u`/0  0(  x  c $Tޜ   x  c $ߜ `    H  0޽h ? 3380___PPT10.u$  P$$(  $r $ S <ݣ `P   r $ S ݣ `  H $ 0޽h ? +T3f3f80___PPT10.uQ$  `($(  (r ( S   `P   r ( S  `  H ( 0޽h ? +T3f3f80___PPT10.u`$  p,$(  ,r , S \ `P   r , S  `  H , 0޽h ? +T3f3f80___PPT10.uu$  0$(  0r 0 S  `P   r 0 S  `  H 0 0޽h ? +T3f3f80___PPT10.u`"$  4$(  4r 4 S  `P   r 4 S  `  H 4 0޽h ? +T3f3f80___PPT10.u D  h$(  hr h S  `P   r h S t `  H h 0޽h ? +T3f3f$  8$(  8r 8 S 0& `P   r 8 S & `  H 8 0޽h ? +T3f3f80___PPT10.u`C$  <$(  <r < S 4+ `P   r < S + `  H < 0޽h ? +T3f3f80___PPT10.ul$  @$(  @r @ S 9 `P   r @ S HF `  H @ 0޽h ? +T3f3f80___PPT10.u q$  D$(  Dr D S K `P   r D S DL `  H D 0޽h ? +T3f3f80___PPT10.u$  H$(  Hr H S Z `P   r H S  [ `  H H 0޽h ? +T3f3f80___PPT10.ur$  L$(  Lr L S 4c `P   r L S c `  H L 0޽h ? +T3f3f80___PPT10.u9$  P$(  Pr P S $l `P   r P S l `  H P 0޽h ? +T3f3f80___PPT10.u`$   T$(  Tr T S Px `P   r T S x `  H T 0޽h ? +T3f3f80___PPT10.uOx$  0X$(  Xr X S  `P   r X S  `  H X 0޽h ? +T3f3f80___PPT10.uPp[}  @`$(  `r ` S h `P   r ` S $ `  H ` 0޽h ? +T3f3f  Pd$(  dr d S l `P   r d S ( `  H d 0޽h ? +T3f3f  `l$(  lr l S   `P   r l S ܡ `  H l 0޽h ? +T3f3fr`p$6@ALyNPRT)WA[m]_acfIhujl?FnpUYr tOh+'0Q hp    ,4$Overview of FDA Device Regulations Bob AssenzoDA  TexturednzoJohn Td21nMicrosoft Office PowerPoint@ПD9@ ŗu@ڍGPg  R('& &&#TNPP`2OMi & TNPP &&TNPP     'A x(xKʦ """)))UUUMMMBBB999|PP3f3333f333ff3fffff3f3f̙f3333f3333333333f3333333f3f33ff3f3f3f3333f3333333f3̙33333f333ff3ffffff3f33f3ff3f3f3ffff3fffffffff3fffffff3f̙ffff3ff333f3ff33fff33f3ff̙3f3f3333f333ff3fffff̙̙3̙f̙̙̙3f̙3f3f3333f333ff3fffff3f3f̙3ffffffffff!___wwweBeBBBB_BeB_BBBBeB?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`acdefghijklmnopqrstuvwxyz{|}~Root EntrydO)PicturesMCurrent UserSummaryInformation(b RPowerPoint Document('uDocumentSummaryInformation8